NCT02227199 2025-11-18
BV-ICE
University of Washington
Phase 1/2 Completed
Clinical Trials
16 trialsNCT02979522 2025-11-10
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
Takeda
Phase 1/2 Active not recruiting
NCT03187210 2025-03-30
BAL
Insel Gruppe AG, University Hospital Bern
Phase 1/2 Suspended
NCT01492088 2024-05-30
Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
Takeda
Phase 1/2 Completed
NCT02572167 2022-11-08
A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
Seagen Inc.
Phase 1/2 Completed
NCT02098512 2022-10-27
Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients
New York Medical College
Phase 1/2 Unknown
NCT02429375 2022-05-12
Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT02686346 2021-12-07
BV-ICE
The Lymphoma Academic Research Organisation
Phase 1/2 Completed
NCT01780662 2021-10-28
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01657331 2020-07-17
SGN+Benda
Columbia University
Phase 1/2 Completed
NCT02729961 2019-10-10
Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma
University of Washington
Phase 1/2 Withdrawn
NCT02243436 2019-04-24
Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 1/2 Completed
NCT01874054 2019-02-12
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma
Seagen Inc.
Phase 1/2 Completed
NCT00354107 2018-03-14
Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT02408042 2017-06-27
Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)
Western Regional Medical Center
Phase 1/2 Withdrawn
NCT00051597 2011-10-12
A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies
Seagen Inc.
Phase 1/2 Completed